Share this article
Share this article
MILAN, Italy, Feb. 1, 2021 /PRNewswire/ Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer s disease (AD), today announced the publication of three new scientific studies that support the utility of its biomarker assay to identify individuals at high risk for AD. The publications describe the role of a conformational variant of the p53 protein ( U-p53
AZ) in the pathogenesis of AD, as well as its applicability as a predictive biomarker to identify individuals likely to progress to AD up to six years before symptoms appear. Two of the papers report the results of early studies that confirm the accuracy of the U-p53